RVU — Ryvu Therapeutics SA Income Statement
0.000.00%
Last trade - 00:00
- PLN1.23bn
- PLN1.02bn
- PLN46.86m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.8 | 15.7 | 11.2 | 38.9 | 46.9 |
Cost of Revenue | |||||
Gross Profit | -9.01 | 6.89 | -25.5 | -0.644 | 21 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 49.2 | 51.3 | 89.8 | 117 | 148 |
Operating Profit | -45.4 | -35.7 | -78.6 | -78.4 | -101 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -44.1 | -30.6 | -79 | -79.2 | -92.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44.3 | -31.7 | -79.1 | -83.8 | -92.1 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 286 | -31.7 | -79.1 | -83.8 | -92.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 286 | -31.7 | -79.1 | -83.8 | -92.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.77 | -1.89 | -4.31 | -4.61 | -4.02 |
Dividends per Share |